Preparation for treatment and prevention of mastitis in cows

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.

EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.

4 tbl, 10 ex

 

The technical field to which the invention relates.

The invention relates to veterinary medicine, in particular to the drug for the treatment and prevention of mastitis in cows, and can be used in obstetrics and gynecology at the creation of medicines for the treatment and prevention of acute postpartum mastitis in cows.

The level of technology

Well-known medication for the treatment of mastitis in cows that contains plant-based and ammonia, while it additionally contains dimexide, and as a vegetable basis - BMF obtained in the production of oil from pumpkin seeds, and media type Aerosil-380 in the following ratio of initial components, wt.%:

- 30% solution of Dimexidum - 4-5,

- 0,5% solution of ammonia) - 2-4,

carrier Aerosil-380 - 2-5,

- BMF - other (see http://naT.RU No. 2170085, IPC A61K 31/00, A61K 35/78, A61P 15/00 publ. 10.07.2001 g).

The disadvantage of this drug is its low efficiency.

Known chemotherapeutic agent used for the treatment of endometritis in cows by intrauterine injection of iodine, the main active ingredient of which is molecular iodine (see Grigorieva I.e., Treatment and prevention of endometritis in cows. M: Rosagropromizdat, 1988, S. 40-41).

The disadvantage of applying iodine is unilateral antiseptic action is s drug on the background of a possible irritant action of iodine on the tissue of the uterus it may not happen the processes aimed at the rapid formation of local immunity.

Known means for preventing mastitis containing polyvinyl alcohol and distilled water, it additionally contains polyvinyl alcohol brand 11/2 and liquid soap disinfectant effect "Clendenin-soft" in the following ratio of components, wt.%:

polyvinyl alcohol varieties 11/2 - 2,0-6,0,

"Clendenin-soft - 0,7-1,0,

- distilled water - other (see U.S. Pat. RU # 2352324, IPC A61K 31/00, A61P 31/02, publ. 20.04.2009,).

The disadvantage of this tool is that this drug does not exert a wide spectrum of action, such as it is inactive against aerobic Gram+ and Gram - bacteria.

Well-known medication for the treatment of mastitis in cows in lactation period, containing dioxidine, further comprises xanthan resin, lactam tetramethylenedisulfotetramine and methyluracil in the following ratio of components, wt.%:

- xanthan gum - 0,18,

- lactam tetramethylenedisulfotetramine to 3.0,

- methyluracil - 0,5,

- distilled water - 05,32 (see U.S. Pat. RU # 2491069, IPC A61K 31/43, A61P 15/14, publ. 27.08.2013,).

The closest in technical essence and the achieved positive effect and adopted is a matter for the prototype is a tool for the treatment of animals with postpartum endometritis, including antimicrobial and anti-inflammatory drugs and a polymer base, at the same time as antimicrobials it contains ethacridine lactate and cefotaxim, as an anti-inflammatory drug - juice scarlet in the following ratio of components, wt.%: ethacridine lactate 0,6; juice of aloe 50.4; cefotaxim 2, urea 15,0; neutral formalin 10; distilled water 5; glycerin 17,0 (see http://naT.RU No. 2367416, IPC A61K 31/047, A61K 1/115, A61K 31/17, A61K 31/473, A61K 36/886, A61P 15/00, publ. 20.09.2009,).

The disadvantage of this tool is that it does not possess antihistaminic activity, and it is not relieves spasms of smooth muscles, reduces capillary permeability, as the inflammatory process leads to increased sensitivity to products of tissue breakdown and the antigens of the bacterial cell.

Disclosure of inventions

The task of the invention is the development of a drug for the treatment and prevention of mastitis in cows with strong antimicrobial and anti-inflammatory wide spectrum of action with a simultaneous decrease in the body's response to histamine, relieving spasms of smooth muscles and decrease capillary permeability.

The technical result that can be obtained using the present invention, is reduced to a pronounced antimicrobial and PR is tivovospalitiona a wide spectrum of action with a simultaneous decrease in the body's response to histamine, removal of muscle spasm and decrease capillary permeability.

The technical result is achieved by using a drug for the treatment and prevention of mastitis in cows containing antimicrobial, anti-inflammatory drugs and distilled water, it also contains licorice root, and as an antimicrobial product contains metronidazole, and as an anti-inflammatory drug - ciprofloxacin, in the following ratio of components, g/l:

- licorice root 80-85 g;

- metronidazole 3,5-4,0 g;

- ciprofloxacin 2,0-2,5 g;

- distilled water - the rest.

The essence of the preparation of a drug for treatment and prevention of mastitis in cows is as follows.

The licorice root in the amount of 80-85 g pour 0.5 liters of distilled water at a temperature of 1000C, incubated for 30-35 minutes, then take in 100 ml of distilled water and dissolve in it the following medications:

is metronidazole in the amount of 3.8-4.0 g pre-pulverized in a mortar, dissolve in 100 ml of distilled water;

is ciprofloxacin, in the amount of 2.0-2.5 g pre-pulverized in a mortar, dissolve in 100 ml of distilled water, then all the components are mixed and 1 litre.

Thus, the use of the proposed drug licorice root, which will win licorise, glycyrrhizinic acid, flavonoids, mucilage and has anti-inflammatory, antispasmodic and cytoprotective effects, metronidazole and which has antimicrobial and antibacterial action, active against anaerobic microorganisms and protozoa, certain Gram+ microorganisms, ciprofloxacin, which is an antibacterial drug group fluoroquinolones 2nd generation broad-spectrum, acting mainly on Gram+ and some Gram - bacteria, and which reduces the body's response to histamine, relieving spasm of smooth muscles, anti-inflammatory effect, reducing capillary permeability, is achieved technical result, namely: expressed antimicrobial and anti-inflammatory wide spectrum of action with a simultaneous decrease in the body's response to histamine, removing spasm of smooth muscles and decrease capillary permeability.

A brief description of the drawings and other materials

Table 1 provides a drug for the treatment and prevention of mastitis in cows, the organoleptic properties of the drug.

In table 2, too, the results of the organoleptic study and Toxicological properties of the drug during storage.

In table 3, too, the study of Toxicological parameters of the drug.

In table 4, too, the study of al is engizirmagi of action of the drug.

The implementation of the invention

Examples of specific performance gain drug for the treatment and prevention of mastitis in cows.

Example 1. The proposed drug for the treatment and prevention of mastitis in cows is prepared as follows.

The licorice root in the amount of 75 g pour 0.5 liters of distilled water at a temperature of 100°C, incubated for 25 min, then take in 100 ml of distilled water and dissolve in it the following medications:

is metronidazole in the amount of 3.5 g pre-pulverized in a mortar, dissolve in 100 ml of distilled water;

is ciprofloxacin, in the amount of 1.5 g pre-pulverized in a mortar, dissolve in 100 ml of distilled water, then all the components are mixed and 1 litre.

While licorice root contains licorise, glycyrrhizinic acid, flavonoids, mucilage and has anti-inflammatory, antispasmodic and cytoprotective effect;

the metronidazole has antimicrobial and antibacterial effect, is an antibacterial drug and active against anaerobic microorganisms and protozoa, certain Gram+ microorganisms;

- ciprofloxacin is an antibacterial drug group fluoroquinolones 2nd generation broad-spectrum, acting mainly on Gram+ and some Gram - bacteria.

Receiving the hydrated drug tested for the treatment and prevention of acute mastitis in cows.

Treatment of mastitis:

after divania milk from diseased part of the udder of the cow nutrizionale enter solution at a dose of 50 ml once a day until recovery. Milk from diseased part of the udder disposed of;

- conduct impact on biologically active points (BAP) low-frequency pulse current in the field of udder for 2 min with an interval of 12 h before recovery.

Recovery cows took place over three weeks.

Prevention of mastitis:

for 5-6 days before calving spend acupressure in the lumbar region and pelvis device, such as Vocals In" acting on biologically active points (BAP) low-frequency pulse current for 1 min every 12 h for 5 days;

- from the first day after calving spend antiseptic treatment of the teats of the udder of the proposed drug for 7 days after each milking.

for 5-6 days before bringing the cows in the total herd spend acupressure in the lumbar region, pelvis and udder device, for example, "the Vocals In" acting on biologically active points (BAP) low-frequency pulse current for 1 min every 12 h for 5 days.

The result: the recovery of the cows were held within twenty-one days.

Example 2. Carried out analogously to example 1, but take components in the following quantities: - the licorice root in the amount of 80 g for the more 0.5 l of distilled water at a temperature of 100°C, incubated for 30 min, then take in 100 ml of distilled water and dissolve in it the following medications:

is metronidazole in the amount of 3.8 g, pre-pulverized in a mortar, dissolve in 100 ml of distilled water;

is ciprofloxacin, in the amount of 2.0 g, pre-pulverized in a mortar, dissolve in 100 ml of distilled water, then all the components are combined, add distilled water to 1 liter.

The results: the drug is tested for the treatment and prevention of acute mastitis in cows, recovery cows held within fourteen days.

Example 3. Carried out analogously to example 1, but take components in the following amounts: - the licorice root in the amount of 85 g pour 0.5 liters of distilled water at a temperature of 100°C, incubated for 35 min, then take in 100 ml of distilled water and dissolve in it the following medications:

is metronidazole in the amount of 4.0 g, pre-pulverized in a mortar, dissolve in 100 ml of distilled water;

is ciprofloxacin, in the amount of 2.5 g, pre-pulverized in a mortar, dissolve in 100 ml of distilled water, then all the components are combined, add distilled water to 1 liter.

The results: the drug is tested for the treatment and prevention of acute mastitis in cows, recovery cows passed over h is tiradritti days.

Example 4. Carried out analogously to example 1, but take components in the following amounts:

- licorice root 90 g pour 0.5 liters of distilled water at a temperature of 100°C, incubated for 40 min, then take in 100 ml of distilled water and dissolve in it the following medications:

is metronidazole in the amount of 45 g pre-pulverized in a mortar, dissolve in 100 ml of distilled water;

is ciprofloxacin, in the amount of 3.0 g pre-pulverized in a mortar, dissolve in 100 ml of distilled water, then all the components are combined, add distilled water to 1 liter.

The results: the drug is tested for the treatment and prevention of acute mastitis in cows, the recovery of the cows was also within fourteen days, but increased consumption of components.

Thus, the best examples are the examples 2 and 3, since the drug with a given number of components gave a positive result.

Drug for the treatment and prevention of mastitis in cows according to the invention was tested in the laboratory of obstetrics and gynecology, Department of veterinary medicine Stavropol scientific research Institute of livestock and fodder production for the treatment and prevention of acute postpartum mastitis in cows and presents examples tested by the deposits of preparation: - the organoleptic properties of the drug (table 1);

the results of the organoleptic study and Toxicological properties of the drug during storage (table 2);

- determination of chronic toxicity, experiments on white mice (table 3);

- allergenicity of the proposed drug (table 4).

Example 5. Physico-chemical properties of the drug for the treatment and prevention of mastitis in cows.

The drug is a complex drug that is not subject to long-term storage. The active components of the drug are antibacterial agents ciprofloxacin and metronidazole, its bioactive components of licorice root. The drug is produced by grinding and dissolving active substances in the decoction of licorice root according to example 2 and 3.

The resulting product is a fine suspension of a brownish color (see table 1), with a faint odor of licorice, storage separate from the formation of a dark brown color. In the stability studies of the drug vials drug incubated 7 days at room temperature protected from light. Daily assess the organoleptic parameters of the drug and inject the slurry into the stomach white mice (three heads) in the test dose of 0.6 ml as a result of the research showed that the drug is on the second the duck store has changed its color to dark brown, happened a lot of mucus. The supernatant acquired a brown tint. Color from the third day of observation had the odor of fermentation. With the introduction of laboratory animals in the test dose on the third day of the study, diarrhea was observed, however, death is not registered.

Thus, the proposed drug is unstable in storage and must be prepared immediately before use. In exceptional cases it is possible to store the drug at the temperature of 4-6°C not more than a day.

Example 6. The study of Toxicological parameters of the drug.

Determination of acute toxicity.

To determine the acute toxicity of the drug use the methods outlined in "guidelines for the Toxicological evaluation of new drugs for the treatment and prevention of non-contagious diseases of animals" approved Century. So Samokhina (1987). The experience carried out on outbred mice. According to the principle of analogs selected 48 animals with a body weight of 22.0±0.6 g and formed 6 groups of mice (n=8), watering and feeding which was discontinued for 4 hours before the start of the experiment. The lowest toxic dose of a drug is determined by the most toxic drug, included in its composition - ciprofloxacino. Mice of the first group into the stomach using a metal probe is injected 0.1 ml of drug - 0.25 mg, animals of the second group of 0.2 ml, RETA - 0,3, fourth - 0.4 ml, fifth - 0.5 ml, sixth - 0,6 ml After drug administration food give three hours. Observation of the mice carry out within 72 hours, account activity, appetite, coat condition, record the deaths of animals.

Mouse first, second, third and fourth groups within 20 minutes after administration of the drug were slightly depressed, was huddled in the corner of the cell, then behave actively. After giving food eaten with appetite. During the remaining time observation of changes in behavior and General condition were observed.

Mouse fifth and sixth groups within 5 minutes after administration of the drug was observed inspiratory dyspnea during 1-1,5 hours mice were oppressed, hair disheveled, lost in the corner in a heap, the appetite was absent. The condition of the animals was normalized within 3 hours.

Deaths were observed in any of the groups. The obtained data allowed to include the proposed drug to a group of low-toxic drugs.

Example 7. The study of the chronic toxicity of the drug.

To determine chronic toxicity experiment was carried out on an accelerated determination of the cumulative effect. We selected 20 nonlinear white mice weighing 18-25 grams. According to the principle analogues formed two groups (n=10). The drug is administered nutrigen docno using a metal probe on a daily basis. Mice of the control group in the same way enter distilled water. Within 4 days of the drug given at a dose of 1000 mg/kg the Following four days the animals receiving the drug at the rate of 2000 mg/kg Within 9-15 days experience dose is 4000 mg/kg From 15 to 20 day mouse get the drug at the rate of 8000 mg/kg

Observation carried out daily throughout the period of experiment. When assessing the condition of the mice take into account the shape of animals, their activity and appetite.

The clinical condition of the animals during the first and second periods of experience remained within the normal range, the mice were active, with appetite took food, wool smooth. 9-day experience, it was noted that animal fur was ruffled, dull, reaction to external stimuli inhibited, rats have long sat at the feeders, then slowly began to eat. With 15 days was a noticeable delay in the growth of the mice of the experimental group compared to control group mice, wool became rare, ruffled, mouse for a long time sat at the feeders, and then slowly started eating, the fatness of the animals of the experimental group was below average. The condition of the rats of the control group throughout the observation period remained satisfactory.

Total median lethal dose with multiple introduction was 88000 mg/kg

To determine what umalali use the formula:

To=LD50x/LD50owhere

K - coefficient of cumulation;

LD50x- average lethal dose with multiple introduction;

LD50o- median lethal dose in a single.

Todrug=88000/10000-8,8

The cumulation coefficient equal to 8.8, which considers the drug to the fourth group is weakly expressed degree of cumulation.

Example 8. The study of the allergenic effects of the drug.

The study of the allergenic activity of the drug (see table) is conducted by the method of cutaneous applications. To do this, we have formed 2 groups of outbred rabbits, 5 animals each. Rabbits first group daily sensibiliser multiple applications (n=24), the drug is in the same area of skin on the side with a diameter of 5 cm every 4 hours for four days. The second group (control) sensibiliser multiple applications (n=24) horse serum in 0.1 ml every 4 hours for 4 days in a row.

After 72 hours (on day 7) conduct drop tests. In the experimental group using the drug according to the invention, in the control of horse serum.

Accounting reactions are every 24 hours, paying attention to the signs of development of dermatitis in places drip samples.

Experience no allergenic effects of the drug.

Example 9. Locally astragals effect of the drug.

To determine the irritant drug use method conjunctival samples. For holding the conjunctival samples using three Guinea pigs. Animals once on the conjunctiva under the upper eyelid of the left eye with a sterile pipette, introduce one drop of the drug according to the invention. Right eye serves as a control, it will intelliroute one drop of distilled water. Analysis carried out after 30 minutes, 1, 3, 6, 12, 24, 72 hours, registering the presence of effusions, congestion, density, color of the conjunctiva.

The survey of Guinea pigs after 30 minutes after drug administration noted a slight hyperemia of the conjunctiva and moderate watering, which is natural when introduced into the conjunctival SAC of the poorly soluble substances. These changes gradually disappear after 2-5 hours. In the follow-up of inflammatory reaction, itching, watery eyes was not.

Based on the above results conclude that the drug is according to the invention has no local irritant effect.

Example 10. Determination of antimicrobial properties of the drug.

To determine the antibacterial activity of the drug use disco-diffusion method. For the manufacture of disks, diluted in equal number distilleria the Oh water. One ml of the resulting suspension is used for impregnation of 100 disks of filter paper. Next, the disks move into a sterile Petri dish, which is placed in a thermostat for drying at a temperature of 37°C.

Seeding the culture test field strain of Staphylococcus spend on a dense nutrient medium meat-peptone agar. After planting in sterile conditions on the surface of the agar is placed disks impregnated with the preparation according to the invention. Diffusion of the drug into the agar led to the formation of zones of inhibition of growth of microorganisms around the disks. After incubation cups in thermostat at 37°C for 48 hours to consider the result by measuring the diameter of zone around the disk in millimeters, which was 24±1.6 mm, on what basis they conclude that the integrated product of the present invention are sufficiently active against a field strain of Staphylococcus.

The present invention in comparison with the prototype and other known technical solution has the following advantages:

- expressed antimicrobial and anti-inflammatory wide spectrum of action;

- reduction reactions histamine;

the removal of muscle spasm;

- decrease capillary permeability;

high therapeutic effect;

- improved natural R is sistently organism of cows.

Drug for the treatment and prevention of mastitis in cows

Table 1
The organoleptic properties of the drug
No.Name of indicatorNorm NTD
1Description medicationFine suspension
2Transparency and colorSuspension brown on standing, a precipitate of dark brown color, the supernatant liquid is turbid, light brown color.
3HarmlessnessLD50>10000 mg/kg hazard class 4 according to GOST 12.1.007-76

Drug for the treatment and prevention of mastitis in cows

Table 2
The results of the organoleptic study and Toxicological properties of the drug during storage
IndexThe nature of istica (normal) Days storage
1234567
Appearance and colorSuspension brown on standing, a precipitate of dark brown color, the supernatant liquid is turbid, light brown+------
Smellspecific++-----
Harmlessness in the test dose per mouse, 0.6 mlharmless++-----
+ - corresponding to the criterial indicator
- - does not meet criteria indicator

Drug for the treatment and prevention of mastitis in cows

Table 3
The study of Toxicological parameters
The number of periodIIIIIIIV
Day from the start of the experiment1-45-89-1515-20
The percentage LD500,10,20,40,8
The dose from the LD-1000200040008000
Loss(%)0000
The total dose for the period(per 1 kg of body weight)4000800028000 48000
Total dose(per 1 kg of body weight)4000120004000088000

Drug for the treatment and prevention of mastitis in cows

Table 4
The study of allergic drug action
Medicationno animalThe skin reaction after
drip sample
124872
hourshourshours
The preparation according to the invention1---
2±--
3±--
Control (serum) 1+±-
2+±±
3±
+ infiltration and swelling of the skin (erythema
± alopecia erythema
- no visible reaction

Drug for the treatment and prevention of mastitis in cows containing antimicrobial, anti-inflammatory drugs and distilled water, characterized in that it additionally contains licorice root, and as an antimicrobial product contains metronidazole, and as an anti-inflammatory drug - ciprofloxacin, in the following ratio of components, g/l:
- licorice root 80-85 g;
- metronidazole 3,5-4,0 g;
- ciprofloxacin 2,0-2,5 g;
- distilled water - the rest.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves prescribing proton pump inhibitor with one antibiotic in a dual therapy and with two antibiotics with a triple therapy twice a day within the course of 7-10 days. Helicobacter is eradicated by the separate administration of drugs. The proton pump inhibitor (omeprazole or pantoprazole) is administered two hours before the antibiotic in the dual therapy and four hours before the second antibiotic in the triple therapy. The drugs are taken for the second time 12 hours after the first one. The antibiotics (clarithromycin, amoxicillin or fromilid) are taken with water 250ml.

EFFECT: invention enables providing the more effective eradication of Helicobacter by the exposure of total therapeutic bioavailability of each preparation with underlying permanent gastric alkaline environment.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a cream for medical application for local treatment of bacterial infections and for wound healing, which contains fusidic acid in an amount of 0.1 wt % to 25 wt % and a biopolymer, preferentially chitosan; fusidic acid is formed in situ in an oxygen-free medium; the above cream contains fusidic acid formed in situ by transforming sodium fusidate at adding the acid slowly, with a particle size of an active agent of the substance of 2.33 mcm to 16.3 mcm, while the biopolymer is introduced into a cream base containing at least one ingredient of each type: primary and secondary emulsifying agents specified in a group containing ketostearyl alcohol, ketomacrogol-1000, polysorbate-80, Span-80, paraffin as a wax product, a combined solvent specified in a group containing propylene glycol, hexylene glycol, polyethylene glycol-400, nitric acid or lactic acid and water.

EFFECT: invention provides the high stability of the active ingredient during the whole shelf life.

12 cl, 18 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and represents a composition for inducing an immune response against Staphylococcus aureus (versions), a method for inducing the immune response against Staphylococcus aureus, and a method for eliciting passive immunity against Staphylococcus aureus in an individual. The composition contains an effective amount of the recovered capsular polysaccharide 5 S. aureus conjugated with the CRM197 carrier protein, an effective amount of the recovered capsular polysaccharide 8 S. aureus conjugated with the CRM197 carrier protein, and at least one ingredient specified in a group consisting of an effective amount of the recovered polypeptide of the clumping factor A (ClfA) of S. aureus, an effective amount of the recovered polypeptide of the clumping factor B (ClfB) of S. aureus (ClfB) and an effective amount of the recovered protein MntC of S. aureus. The capsular polysaccharide type 5 represents a capsular polysaccharide of high molecular weight from 70 to 300 kD. The capsular polysaccharide type 8 represents a capsular polysaccharide of high molecular weight from 70 to 300 kD, wherein from 5 to 23 lysines in CRM197 are conjugated. The CP5 and CP8 conjugates have the molecular weight from approximately 200 kD to approximately 5000 kD.

EFFECT: presented invention enables eliciting the improved immune response against Staphylococcus aureus.

25 cl, 29 dwg, 26 tbl, 32 ex

FIELD: medicine.

SUBSTANCE: method involves immunising with 5×107 microbial cells Vibrio cholerae 5879; 10 days later, a common pool of anticholeraic Ig is recovered from enteric washing liquid. That is combined with producing the primary enterocyte culture from intact mice. Thereafter, the doubly-diluted anticholeraic Ig are applied in an amount of 3 ml on a monolayer of erythrocytes formed in wells of culture panels. The latter are added with alive choleraic vibrions of the strain Vibrio cholerae 5879, 40 m.c. per 1 erythrocyte and incubated for 3 hours. Then, the panels are washed three times, fixed with ethanol for 20 minutes and stained by Romanowsky-Giemsa. Local humoral anticholeraic immunity is assessed under the microscope by the number of vibrions stained in dark blue and attached to one erythrocyte.

EFFECT: method enables assessing specific local humoral immunity and intensifying the anti-adhesive activity of the common pool of anticholeraic immunoglobulin.

4 cl, 2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new bacitracin compounds with antibiotic activity

,

wherein at least one of R1, R2 and R3 represents -CH=CH2 and wherein R1, R2 and R3 independently represent -H, -CH3 or -CH=CH2.

EFFECT: preparing the new bacitracin compounds.

13 cl, 8 dwg, 7 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula I and their pharmaceutically acceptable salts, method for preparing them by the fermentation of a microorganism of the species Streptomyces (PM0626271/MTCC 5447), and to their pharmaceutical compositions containing one or more compounds of formula I as an active ingredient.

EFFECT: compounds of formula I are used for treating and preventing the diseases caused by bacterial infections.

4 cl, 3 dwg, 6 tbl, 9 ex

FIELD: biotechnologies.

SUBSTANCE: invention represents a producing method of cream containing fusidic acid, which involves a stage of application of sodium fusidate as an initial active ingredient and conversion of the above sodium fusidate in situ to fusidic acid in an oxygen-free medium by immediate addition of the acid to a cream base containing a preservative, an acid, a cosolvent, an emulsifier, a wax-like product and water.

EFFECT: obtaining cream having high stability at storage and smaller particles of an active ingredient.

9 cl, 11 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents dermatological cream, intended for local treatment of bacterial skin infections and for healing wounds associated with them, which contains framycetin sulfate and biopolymer, included into cream base, which contains at least one substance from each of the following groups: preservative, primary and secondary emulsifier, selected from the group which contains ketostearyl alcohol, ketomacrogol 1000, polysorbate-80 and Span-80; paraffin as wax-like product, cosolvent, selected from the group, including propylene glycol, hexylene glycol and polyethylene glycol-400; nitric acid or lactic acid and water, with said biopolymer preferably being chitosan.

EFFECT: invention provides higher therapeutic effect.

8 cl, 10 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention represents cream for skin infections, containing fusidic acid formed in situ in an oxygen-free medium with the use of sodium fusidate. The above cream contains fusidic acid prepared in situ by the conversion of sodium fusidate with adding acid slowly, with a particle size of the active substance of 2.33 mcm to 16.3 mcm, and the cream base containing at least one ingredient of each type: primary and secondary emulsifying agents specified in a group containing ketostearyl alcohol, ketomacrogol-1000, Polysorbate-80 and Span-80, paraffin as wax, a combined dissolving agent specified in a group including propylene glycol, hexylene glycol, polyethylene glycol 400, nitric acid or lactic acid and water.

EFFECT: invention provides high stability of the active ingredient throughout the whole shelf life.

10 cl, 16 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a pneumococcal vaccine containing saccharide of 4, 6B, 9V, 14, 18C, 19F and 23F serotypes, separately conjugated with CRM197, and at least one Toll-like receptor-9 (TLR-9) agonist as an adjuvant, wherein the above Toll-like receptor-9 agonist represents CpG-oligonucleotide. Also, the group of inventions concerns using the pneumococcal vaccine for preparing the therapeutic agent for preventing or treating diseases caused by S.pneumoniae; a method for individual's immunisation against the diseases caused by S.pneumoniae infection, involving administering the immunoprotective dose of the vaccine into the above individual.

EFFECT: adding B-class CpG to the conjugated pneumococcal vaccine provides the considerable increase of the proportion of highly responsive patients, good tolerance and cell memory induction in relation to pneumococcal polysaccharides.

45 cl, 9 dwg, 4 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: described is novel biologically active compound 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-argininium dehydrate of formula , which has antiviral action, method of its obtaining and application for prevention and treatment of West Nile fever.

EFFECT: increased efficiency of compound application.

3 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula wherein each of R1 and R2 is independently selected from a group consisting of a hydrogen atom, nitro and NR6R7; R3 is C1-C8alkyl; each of R4 and R5 is independently selected from a group consisting of C1-C8alkoxy, phenoxy and phenyl(C1-C8alkylene)oxy; each of R6 and R7 is independently selected from a group consisting of a hydrogen atom, C1-C8alkyl, C(O)R8 and SO2R8;R8 is selected from a group consisting of a hydrogen atom, C1-C8alkyl, halogen-substituted C1-C8-alkyl, C1-C8-alkyl, substituted (C1-C8-alkylsubstituted amino), C1-C8-alkyl, substituted with piperidine and C1-C8-alkyl, substituted with morpholine.

EFFECT: reduced PDE4 enzyme activity and treating PDE4 enzyme mediated diseases or conditions.

21 cl, 2 tbl, 32 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel cocrystals of niflumic acid with isonicotinamide or caffeine, where molar ratio of niflumic acid with isonicotinamide or caffeine constitutes 1:1, and cocrystal of niflumic acid with isonicotinamide has entothermic peak from 152 to 162°C according to the data of measurement by means of differential scanning calorimetry and peaks at 2θ(°) 6.3, 7.4, 12.5, 14.5, 19.2, 23.2, 25.0 by the data of measurement of X-ray radiation difraction on powder, and cocrystal of niflumic acid with caffeine has endothermic peak from 155 to 165°C by the data of measurements by means of differential scanning calorimetry and peaks at 2θ(°) 9.7, 12.0, 13.26, 14.3, 17.0, 18.1, 22.5, 26.2 and 26.9 by the data of measurement of X-ray radiation diffraction on powder.

EFFECT: increase of solubility in water in comparison with indices of niflumic acid solubility in pure form.

12 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) and (II), which possess the blocking activity on voltage-sensitive sodium channels, such as TTX-S channels, and their pharmaceutically salts. In general formula (I) and (II), R1 represents -CF3, -CHF2, -OCF3, -OCHF2, -OCH2CHF2/ -OCH2CF3, -OCF2CHF2; -OCF2CF3, -OCH2CH2CF3, -OCH(CH3)CF3, -OCH2C(CH3)F2, -OCH2CF2CHF2, -OCH2CF2CF3, OCH2CH2OCH2CF3, -NHCH2CF3, -SCF3, -SCH2CF3, -CH2CF3 -CH2CH2CF3, -CH2OCH2CF3 and -OCH2CH2OCF3; R2 is specified in (1) hydrogen, (2) halogen (3) -On-C1-6 alkyl, (4) -On-C3-6 cycloalkyl, (5) -On-phenyl, (6) -On-heterocyclic group, (7) -NR7 (C=O)R8; wherein n is equal to 0 or 1, p is equal to 1, 2; R3 and R4 represents hydrogen or C1-6 alkyl, X represents carbon atom; Y represents hydrogen or C1-6 alkyl; Ar represents 4-pyridyl, 4-pyrimidyl or 6-pyrimidyl, which is substituted in the 2nd position by a substitute, which is independently specified in (1) -(C=O)-NR7R8, (2) -NR7(C=O)R8; R9 is specified in: (1) hydrogen, (2) halogen, (3) -On-C1-6 alkyl, wherein alkyl is unsubstituted or substituted by hydroxyl; q is equal to 1, 2 or 3; R10 independently represents hydrogen, C1-6 alkyl, C2-6alkenyl, C3-7 cycloalkyl or phenyl, which is unsubstituted or substituted by one or substitutes independently specified in hydroxyl, -On-C1-6 alkyl and -C3-7 cycloalkyl.

EFFECT: preparing the compounds possessing the blocking activity on voltage-sensitive sodium channels.

7 cl, 2 tbl, 1281 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new compound, namely to (S)-enantiomer of 1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-f][1,3]benzodioxol-7,3'-indole]-2'(1'H)-one of formula (I), and a method for preparing it which is effective for treating diseases and conditions, such as pain, an intensity of which can be reduced or relieved by modulating potential-dependent sodium channel gatings.

EFFECT: invention refers to the pharmaceutical composition of the above compound, methods of treating and a method of relieving an ion flux through the potassium channel gating in a cell.

10 cl, 5 tbl, 6 dwg, 11 ex

FIELD: medicine.

SUBSTANCE: agent possessing the anti-inflammatory, antipyretic and antimicrobial action representing a dry extract of drug hedge hyssop leaves and blossom by grinding them, extracting in 96% alcohol on a water bath to a boil, and boiling, evaporating, diluting the evaporated residue by distilled water first, adding chloroform then, cooling to a room temperature and centrifuging, separating a water fraction and drying it in the certain environment.

EFFECT: agent possesses the pronounced anti-inflammatory, antipyretic and antimicrobial action.

5 dwg, 5 tbl, 2 ex

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: medicine.

SUBSTANCE: presented group of inventions refers to medicine. What is presented is a method of treating visceral pain and/or one or more symptoms of visceral pain, involving administering a therapeutically effective amount of an antagonist antibody against calcitonin gene-related peptide (CGRP) into an individual suffering visceral pain, or an individual suffering a risk of visceral pain, wherein the CGRP agonist antibody is applicable for peripheral administration. What is also presented is a pharmaceutical composition containing the CGRP agonist antibody and a pharmaceutically acceptable carrier, applicable for peripheral administration.

EFFECT: presented group of inventions provides the effective treatment of visceral pain with using no opiates.

18 cl, 3 dwg, 2 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to lambertianic acid amides of formula (Ia, b), which have expressed analgesic activity and stimulating action, manifested in increase of motor and investigation activity of animals, absence of anxiety, etc. In formula I ; (Ib).

EFFECT: improvement of compound properties.

6 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: in general formula

A represents optionally substituted aminocarbonyl group -N-C(O)-, in which amino group can be substituted and substituents can be selected from hydrogen, C1-C5alkyl, possibly substituted with C1-C3alkoxy, C3-C6cycloalkyl, 5-6-membered heteroaryl, in which heteroatoms are selected from oxygen or nitrogen; aryl, selected from phenyl, possibly substituted with hydroxy, C1-C5alkyl, C1-C5alkoxy, halogen, C1-C5acylamino group, or naphthyl; or amino group is selected from C3-C7heterocyclyl, containing 1-2 heteroatoms in cycle, selected from nitrogen, oxygen or sulphur, possibly substituted with hydroxy, C1-C3alkyl, benzyl, phenyl, which can be substituted with halogen, and said heterocyclyl can be condensed with benzene ring; acylamino group, in which acyl is selected from C1-C6alkylcarbonyl, where alkyl can be substituted with phenyl, substituted with phenyl, in which substituents are selected from C1-C5alkoxy; 5-membered heteroaryl with heteroatom, selected from atom of oxygen or sulphur; benzoyl, possibly substituted with C1-C5alkyl, C1-C5alkoxy, C1-C5alkylthio or halogen, methylenedioxy; heterocyclylcarbonyl, in which heterocyclyl is selected from 5-6-membered heterocyclyl, with 1-2 heteroatoms, selected from nitrogen, oxygen or sulphur, possibly condensed with benzene ring and possibly substituted with C1-C5alkyl, halogen; or ureido group, in which one of substituents of terminal amido group represents hydrogen, and the second substituent is selected from: C1-C3alkyl, substituted with phenyl, 5-membered saturated or aromatic heterocyclyl, in which heteroatoms are selected from oxygen or sulphur; C2-C6alkenyl; aryl, selected from phenyl, substituted with C1-C5alkyl, C1-C5alkoxy, ethylenedioxy, methylenedioxy, halogen, C1-C3alkylcarbonyl; 5-membered heterocyclyl, in which heteroatoms are selected from sulphur or oxygen atom, and possibly substituted with alkyloxycarbonyl group; B represents non-aromatic cyclic substituent, selected from C4-C6cycloalkyl; and has other values, given in the invention formula. Values R1a R1b R1c are given in the invention formula.

EFFECT: increased efficiency of application of compounds.

12 cl, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating and managing the pregnant women suffering drug-induced hepatitis. Establishing a diagnosis of drug-induced hepatitis requires oral administration of the herbal hepatoprotectors Carsil, or Hepabene, or the vitamin-free essential phospholipids Eslidin per os or Essentiale forte N intravenously, per os in standard doses with a cessation of any other drug-induced therapy, in the 1st trimester of pregnancy in case of observing a symptom-free increase of transaminase activity within 3 normal values and no counter-indications. In the 2nd trimester, a serum transaminase level up to 5 normal values requires prescribing ademetionine 400 mg intravenously N 7-10, then per os 1,600 mg/day. The therapeutic course makes 1 month. Ademetionine 800 mg intravenously N 10 + ursodeoxycholic acid 12 mg/kg/day are prescribed if observing the daily serum transaminase level of 5 to 10 normal values. Prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 12 mg/kg/day + prednisolone 90 mg/day is used for the daily serum transaminase level of more than 10 normal values. In the 3rd trimester, the daily serum transaminase level of below 5 normal values requires administering ademetionine 800 mg/day intravenously N10 + ursodeoxycholic acid 13 mg/kg/day. The transaminase level of 5 to 10 normal values requires prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 13 mg/kg/day + prednisolone 90 mg/day intravenously. A progressive increase of the daily transaminase level of above 10 normal values with underlying therapy with ademetionine 800 mg/day intravenously, ursodeoxycholic acid 13 mg/kg/day, prednisolone 120 mg/day intravenously with 3 days expected, a decrease of the daily transaminase level or a stabilization thereof are accompanied by continuing the therapy with the progression follow-up, including hepatic cytolysis values - an increase of the hepatic cytolysis values; an increase thereof is accompanied by prescribing the adequate therapy. The postpartum therapy is continued completely until liver function tests are normalised.

EFFECT: method enables preventing the pregnancy complications ensured by the timely diagnosis of drug-induced hepatitis in the pregnant women, the adequate drug-induced therapy differentiated by gestational age and a degree of manifestation of hepatic cytolysis and aiming at reducing a hepatic pathological process.

6 ex

Up!